Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: poloxamer; phosphoric acid; sucrose; dibasic sodium phosphate dihydrate; water for injections; methionine; metacresol; sodium hydroxide; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: methionine; phosphoric acid; dibasic sodium phosphate dihydrate; sodium hydroxide; poloxamer; sucrose; metacresol; water for injections; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: methionine; phosphoric acid; dibasic sodium phosphate dihydrate; water for injections; sucrose; poloxamer; sodium hydroxide; metacresol; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - sebelipase alfa, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections; albumin - kanuma (sebelipase alfa rce) is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase deficiency (lal-d).

Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - follitropin alfa, quantity: 225 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: sucrose; sodium chloride; sodium citrate dihydrate; poloxamer; calcium chloride dihydrate; arginine hydrochloride - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 2000 iu - injection, powder for - excipient ingredients: arginine hydrochloride; calcium chloride dihydrate; sucrose; sodium chloride; poloxamer; sodium citrate dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: arginine hydrochloride; poloxamer; calcium chloride dihydrate; sodium citrate dihydrate; sucrose; sodium chloride - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.